| Literature DB >> 20970678 |
R Casalegno-Garduño1, A Schmitt, X Wang, X Xu, M Schmitt.
Abstract
Wilms' tumor 1 (WT1) is a leukemia associated antigen (LAA) differentially expressed by leukemic blasts. Thus, WT1 may constitute a target for therapies such as those mediated by adoptive-specific T lymphocytes. Serological and cellular immune responses have been elicited by WT1 in patients with leukemia. Specific CD8+ T cells able to recognize this antigen can be selected by streptamers and then infused into leukemia patients. Potentially, these T cells could lyse leukemic blasts expressing WT1. The only good manufacturing practice-certified technology is streptamers, which are available for antigen-specific T-cell sorting. Immunocompromised patients may have their antigen-specific immune responses restored through the transfer of adoptive T cells specific for this LAA.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20970678 DOI： 10.1016/j.transproceed.2010.07.034
Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066